Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

Queen's University

$59,535.00

Synthesis of deuterium labelled pharmaceutical compounds with improved efficacy

FY 2018-19

Summary
Organic synthesis involves making carbon-based complex molecules from simple ones, just as Lego blocks are*clicked together to form large educational and playful structures. Methods for synthesis have advanced and*multiplied so that today we can make complicated molecules, some of which provide medicines and*agricultural agents for the benefit of humankind. Today, a very active area, especially in industrial laboratories,*is the synthesis of deuterium (D)-containing pharmaceuticals. The replacement of hydrogen (H) of a given drug*with D results in modification/retardation of metabolic fate and alters the therapeutic profile while retaining the*biological potency of the non-D molecules. Thus, the development of D-analogues of currently approved*pharmaceuticals could lead to a positive impact on the safety, efficacy and tolerability of these drugs,*addressing important but unmet medical needs. This proposal aims to address these needs by the synthesis of a*series of D-analogues of currently significant marketed drugs. The proposed research is based on our*considerable experience in the discovery and development of directed ortho metalation (DoM) and related*technologies for the preparation of aromatic and heteroaromatic molecules. These classes of molecules are the*mainstay of pharmaceuticals (80% of modern drugs) and are used by industry (e.g. Monsanto, Pfizer, BMS,*Merck) for the multi-kg synthesis of marketed pharmaceuticals. We also have a strong knowledge base on the*preparation of D-molecules since this is the backbone reaction of our DoM synthetic strategies. Based on this*background and experience, our goals are: a) to incorporate D into commercially available drugs, establishing*synthetic feasibility; b) to develop fundamentally new synthetic steps for introduction of D at early or late*intermediate stages; and c) to develop new routes that truncate known procedures. We anticipate that the*research will provide Sussex Research an advantage over non-Canadian competitors, and thereby will have a*positive impact on the Canadian economy as well as train highly qualified scientists for the Canadian labour*market.
Program
Collaborative Research and Development Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
523925-2018
Name nom
Snieckus, Victor
Department département
Chemistry
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
59535
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Synthesis of deuterium labelled pharmaceutical compounds with improved efficacy
Keyword
NSERC
Application summary
Organic synthesis involves making carbon-based complex molecules from simple ones, just as Lego blocks are*clicked together to form large educational and playful structures. Methods for synthesis have advanced and*multiplied so that today we can make complicated molecules, some of which provide medicines and*agricultural agents for the benefit of humankind. Today, a very active area, especially in industrial laboratories,*is the synthesis of deuterium (D)-containing pharmaceuticals. The replacement of hydrogen (H) of a given drug*with D results in modification/retardation of metabolic fate and alters the therapeutic profile while retaining the*biological potency of the non-D molecules. Thus, the development of D-analogues of currently approved*pharmaceuticals could lead to a positive impact on the safety, efficacy and tolerability of these drugs,*addressing important but unmet medical needs. This proposal aims to address these needs by the synthesis of a*series of D-analogues of currently significant marketed drugs. The proposed research is based on our*considerable experience in the discovery and development of directed ortho metalation (DoM) and related*technologies for the preparation of aromatic and heteroaromatic molecules. These classes of molecules are the*mainstay of pharmaceuticals (80% of modern drugs) and are used by industry (e.g. Monsanto, Pfizer, BMS,*Merck) for the multi-kg synthesis of marketed pharmaceuticals. We also have a strong knowledge base on the*preparation of D-molecules since this is the backbone reaction of our DoM synthetic strategies. Based on this*background and experience, our goals are: a) to incorporate D into commercially available drugs, establishing*synthetic feasibility; b) to develop fundamentally new synthetic steps for introduction of D at early or late*intermediate stages; and c) to develop new routes that truncate known procedures. We anticipate that the*research will provide Sussex Research an advantage over non-Canadian competitors, and thereby will have a*positive impact on the Canadian economy as well as train highly qualified scientists for the Canadian labour*market.